Baudax Bio Acquires TeraImmune, Inc.
TeraImmune, an Advanced Treg Research Company, headed by Yong Chan Kim, Ph D, brings an approved Treg IND to the...
Pharmaceutical
AEON Biopharma and Priveterra Announce Arrangement of Up to $125 Million of Financing in Connection with Proposed Business Combination
Financing represents minimum cash required to consummate the business combination and bridge AEON through key episodic migraine data readoutIRVINE, Calif.,...
CytomX Therapeutics Announces $30 Million Private Placement from BVF Partners L.P.
- Financing is expected to extend cash runway into the 2nd half of 2025 based on current operating plans, enabling...
Enterome announces first patient dosed in a Phase 1/2 trial with third OncoMimics™ immunotherapy, EO4010, in Metastatic Colorectal Cancer
EO4010 uniquely mimics five distinct tumor-associated antigens designed to provide multi-targeted, broad tumor coverage, maximizing tumor killing and preventing immune...
Immuron Chairman Transition
MELBOURNE, Australia, June 30, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated...
Samsung Bioepis Releases 2023 Sustainability Report
Highlights key initiatives that will drive the company’s transition towards a more sustainable businessReaffirms commitment to environmentally and socially responsible...
Spexis announces engagement with Maxim Group LLC as M&A advisor to support evaluation of strategic transactions
Ad hoc announcement pursuant to Art. 53 LR ALLSCHWIL, Switzerland, June 29, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX),...
ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2023 Annual General Meeting held on June 29, 2023
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – June 30, 2023 –...
Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE® trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease
Trial met primary endpoint with a statistically significant higher percentage of patients achieving a clinically meaningful cholestasis response compared to...
Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease
Trial met primary endpoint with a statistically significant higher percentage of patients achieving a clinically meaningful cholestasis response compared to...
PETVIVO HOLDINGS, INC. ANNOUNCES RESCHEDULED EARNINGS CALL FOR THE YEAR ENDED MARCH 31, 2023
MINNEAPOLIS, MN, US, June 29, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV and PETVW), an emerging biomedical device...
Ardelyx, Inc. Reports Employment Inducement Grants
WALTHAM, Mass., June 29, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover,...
Zymeworks Appoints New Director
VANCOUVER, British Columbia, June 29, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional...
Vir Biotechnology Appoints Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer
SAN FRANCISCO, June 29, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Sasha Damouni...
Curia wins 2023 Frost & Sullivan Customer Value Leadership Award
Curia recognized for providing a best-in-class customer experience in the CRDMO industry through its innovative approach and growth strategyALBANY, N.Y.,...
Evelo Biosciences Announces Reverse Stock Split Effective
– EVLO common stock expected to begin trading on a split-adjusted basis on June 30, 2023 – CAMBRIDGE, Mass., June 29,...
Aquestive Therapeutics Provides Business Update and Announces Chief Medical Officer Appointment
Submitted NDA for Libervant™ (diazepam) Buccal Film for treatment of seizure clusters in patients between two and five years of...
Elucent Announces Key Executive Appointments to Chief Executive Officer & Chief Financial Officer
Jason Pesterfield, Veteran Med-Tech Executive and Growth Strategist, Named President, and CEO Kirk G. Jacquay, Seasoned Finance & Operations Leader,...
NeuBase Presents Non-Human Primate Data Illustrating Stealth Editors™ are Non-Immunogenic, Opening the Door to Redosing
New preclinical data validates that Stealth Editors™ are non-immunogenic, as featured in a poster presentation at the 28th American Peptide...
Pasithea Therapeutics Announces Completion of GMP Manufacturing for PAS-004
-- Represents the final step before submission of Investigational New Drug (IND) application to FDA, expected in the second half...